Home Companies Catalysts Deep Dives
POETYK PSO-1 PHASE3 COMPLETED
Drug: Sotyktu · BMY
Study Design
DesignRandomized, double-blind, placebo and active-controlled
BlindingDouble-blind
NCTNCT03624127
Treatment Arms
Deucravacitinib 6mg QD 6mg oral once daily
Apremilast 30mg BID 30mg oral twice daily
Placebo Matching oral placebo
Primary Endpoints
[{"id":"pasi75-w16","name":"PASI 75 at Week 16","type":"PRIMARY","unit":"%","results":[{"value":58.4,"arm_id":"deuc-arm","p_value":0.001},{"value":35.1,"arm_id":"apr-arm"},{"value":12.7,"arm_id":"pbo-arm"}],"timepoint":"Week 16","description":"Note: primary endpoint was PASI 75 (lower bar than most newer trials)."}]
Assessment
Beat Otezla but these are modest numbers for modern psoriasis. PASI 90 ~36% puts Sotyktu far below injectable biologics. Primary endpoint was PASI 75 — the low bar needed because TYK2 efficacy is limited. Now obsoleted by icotrokinra H2H in ICONIC-ADVANCE.
Data from Supabase · Updated 2026-03-24